More than a year has passed since that was posted. Thanks for bringing it to the board.

For those who think an Afrezza approval brings an immediate 20% market penetration that isn't usually how it works. If one counts the type 2 market and we end up with a 5% piece of the entire US market in a couple of years it will be amazing. We are more likely to see acceptance from PCP's 6-12 months after approval as they are made aware of the drug's impact to the patient's quality of life.

Remember the current studies are based upon non-inferiority not superiority. Al has continually tried to impress upon us over the past few years he does not agree with basing the efficacy upon the impact on A1C's. I think Al is in minority in that thinking based upon what endocrinologists focus on.